Lutetium prostate cancer treatment for limited PSMA-spread
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 3 trial compares a targeted radiation medicine called lutetium (177Lu) vipivotide tetraxetan versus watchful waiting in people with prostate cancer that has spread to only a few spots. The goal is to see if the treatment can better control the cancer when scans show a small amount of PSMA-positive metastases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had prostate cancer confirmed by biopsy/pathology before joining the trial
- Your prostate cancer must come back based on PSA blood tests after prior definitive local treatment (surgery and/or radiation)
- Your PSMA PET/CT scan shows 1–5 PSMA-positive metastatic spots, and at least one must be in distant sites (not just nearby/adjacent)
- Your scan must show a negative result for certain distant disease findings on a second imaging check (CI must be negative for M1)
- All cancer spots found at screening must be suitable for stereotactic body radiation therapy (SBRT)
- Your testosterone level must be above 100 ng/dL (not chemically suppressed) at screening
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of focused radiation (SBRT) and a targeted radioactive drug (Lutetium PSMA) for men with prostate cancer that has spread to nearby lymph nodes or has high-risk features but has not yet reached distant organs. The goal is to see if this approach is safe and effective.
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
This study tests a new treatment called 177Lu-PSMA given after standard therapy (surgery or radiation) to see if it can prevent prostate cancer from coming back. It is for patients with high or very high-risk prostate cancer that hasn't spread yet.
This trial tests a radioactive drug called Lutetium-177 (Lu-177) that targets and kills prostate cancer cells showing a specific marker (PSMA). It's for men with advanced prostate cancer that has spread and stopped responding to hormone therapy, and who have already tried certain chemotherapy or cannot have it.
This study is observing how well the treatment lutetium-177-PSMA-617 works in people with metastatic castration-resistant prostate cancer. It aims to gather real-world information about its effectiveness and safety.
This study follows men with advanced prostate cancer who are receiving a new radioactive treatment called lutetium (177Lu) vipivotide tetraxetan. The goal is to see how well the treatment works in everyday practice, and to gather information on safety and effectiveness.
Hear when a new Oligometastatic Prostate Cancer (OMPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.